AOD-9604 + MOTS-c Stack: Safety and Monitoring for Women

What Are AOD-9604 and MOTS-c, and Why Do Women Stack Them?

AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176 to 191). It was developed by Monash University researchers to retain the fat-metabolizing properties of GH without stimulating IGF-1 or causing insulin resistance. Early clinical work showed dose-dependent lipolysis in obese adults, and the compound briefly entered Phase II trials for obesity before development was halted for commercial reasons, not safety signals.

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It regulates glucose uptake via AMPK activation and has shown insulin-sensitizing effects in mouse models. A 2015 Cell paper by Lee et al. identified MOTS-c as a mitochondrial-derived peptide that improves skeletal muscle insulin sensitivity and reduces diet-induced obesity in male mice. That study involved only male animals. Women are using it anyway, which is a meaningful evidence gap covered in detail below.

The combination appeals to women who want to reduce visceral fat and improve metabolic markers simultaneously, using two mechanisms thought to be complementary: AOD-9604 acts primarily on lipolysis in adipocytes, while MOTS-c improves mitochondrial efficiency and glucose handling in muscle. Whether those mechanisms actually add up in women, at the doses practitioners are recommending, has not been tested in a controlled trial.

Why Women Are a Distinct Population Here

Women carry more subcutaneous fat and less visceral fat than men at equivalent BMI, a pattern that shifts after menopause when estrogen withdrawal redirects fat storage toward the abdomen. Research published in Obesity Reviews confirms that postmenopausal women show visceral fat accumulation rates similar to age-matched men, a change driven primarily by the loss of estradiol's protective effect on fat partitioning.

GH pulsatility also differs by sex. Women have more frequent GH pulses than men, but those pulses are blunted in perimenopause and further reduced after menopause. Data from the Journal of Clinical Endocrinology and Metabolism show that GH secretion in postmenopausal women is approximately 25 percent lower than in premenopausal women of similar weight. Because AOD-9604 works downstream of GH receptor signaling, this background GH environment may influence how the peptide performs, though no study has compared AOD-9604 response across menopausal status.

The Evidence Base: What Is Actually Known

This section is blunt. The evidence base for this stack in women is limited and extrapolated.

AOD-9604: What the Trials Show

AOD-9604 completed at least three small Phase II trials funded by Metabolic Pharmaceuticals (Australia). The most cited, Norman et al. (2009), found that oral AOD-9604 at 1 mg/kg/day produced statistically significant fat loss at 12 weeks versus placebo in adults with BMI between 27 and 40. The trial included both men and women, but sex-stratified results were not reported. The FDA granted AOD-9604 GRAS (Generally Recognized as Safe) status as a food additive in 2014, based on oral dosing data. That designation does not extend to injectable subcutaneous use, which is how most practitioners currently administer it.

No published study has specifically examined subcutaneous AOD-9604 dosing in perimenopausal or postmenopausal women.

MOTS-c: What the Trials Show

Human data on MOTS-c is sparse. A 2019 study in Aging found that circulating MOTS-c levels in humans decline with age and that lower levels correlate with insulin resistance and obesity. The researchers measured MOTS-c in 156 participants, but did not perform a therapeutic intervention. Exogenous MOTS-c administration in humans has not been described in any peer-reviewed publication as of this writing. All therapeutic dosing protocols circulating online are extrapolated from mouse data scaled to human body weight, then modified through practitioner experimentation. That is not a clinical trial. Say that clearly when evaluating any protocol.

The table below organizes what is directly studied versus what is extrapolated, so you can weigh evidence quality yourself.

| Claim | Source | Evidence Quality | |---|---|---| | AOD-9604 causes fat loss in obese adults | Norman et al., Phase II RCT | Moderate (small n, industry-funded, sex-unstratified) | | AOD-9604 does not raise IGF-1 | Heffernan et al., J Endocrinol | Moderate (animal + limited human) | | MOTS-c improves insulin sensitivity | Lee et al., Cell 2015 | Low for women (male-only mouse model) | | MOTS-c declines with aging | Kim et al., Aging 2019 | Moderate (observational, mixed sex) | | The combined stack is effective | No published study | Not established | | Subcutaneous AOD-9604 is safe long-term | No published study | Not established |

Sex-Specific Physiology: How Hormonal Status Changes the Picture

Estrogen and Fat Metabolism

Estradiol upregulates beta-3 adrenergic receptors on adipocytes, the same receptors that AOD-9604 is thought to stimulate for lipolysis. A review in Endocrine Reviews explains that estrogen deficiency reduces lipolytic receptor sensitivity, which may blunt the fat-releasing effect of compounds acting through this pathway. This has not been studied for AOD-9604 specifically. The practical implication: postmenopausal women using this peptide without concurrent estrogen therapy may get a smaller response than the Phase II trials (which included premenopausal women) suggested.

The Menstrual Cycle and Insulin Sensitivity

MOTS-c's proposed benefit is insulin sensitization via AMPK. Insulin sensitivity in women fluctuates across the menstrual cycle, with the luteal phase (days 15 to 28) associated with relative insulin resistance compared to the follicular phase. Data from Diabetes Care confirm approximately a 26 percent reduction in insulin-mediated glucose disposal in the late luteal phase. If MOTS-c does improve insulin sensitivity, its functional effect may appear larger when started in the follicular phase, though no study has tested this timing hypothesis.

PCOS

Women with polycystic ovary syndrome have baseline insulin resistance and, in many cases, higher circulating androgens that promote visceral fat accumulation. Both targets are theoretically aligned with this stack's proposed mechanisms. No PCOS-specific MOTS-c trial exists. A 2024 systematic review in Fertility and Sterility found that mitochondrial dysfunction is prevalent in women with PCOS and may contribute to their metabolic phenotype, lending some biological rationale to the idea that a mitochondria-targeting peptide could help, without proving that MOTS-c does.

Perimenopause and Menopause

The perimenopausal years (typically mid-40s) bring erratic estrogen fluctuations, rising FSH, declining GH pulsatility, and a gradual shift toward central adiposity. These changes align precisely with what this stack targets. A number of functional medicine and anti-aging practitioners specifically promote the AOD-9604 plus MOTS-c combination for this population. The framing is plausible. The evidence that it works better than, say, resistance training plus adequate protein in perimenopausal women is absent.

Pregnancy, Lactation, and Contraception

Both peptides are contraindicated during pregnancy and breastfeeding. No safety data exist in pregnant or lactating women.

AOD-9604 is a fragment of human growth hormone. GH signaling plays a direct role in fetal growth, placentation, and IGF-1-mediated organogenesis. Disrupting that system with exogenous fragments during pregnancy carries theoretical teratogenic risk. No animal reproductive toxicology studies for AOD-9604 are publicly available, which means there is no safety floor, not that it is safe.

MOTS-c has no published reproductive toxicology data at all. The peptide is encoded in mitochondrial DNA and influences mitochondrial function broadly. Mitochondrial integrity is critical for oocyte quality, early embryo development, and placental function. A review in Biology of Reproduction describes how mitochondrial dysfunction impairs oocyte competence and early embryogenesis. Introducing an exogenous mitochondria-modulating peptide during that window is not something any clinician can call safe.

Contraception requirement: Any woman of reproductive age using this stack must use reliable contraception. If you are actively trying to conceive, do not use either peptide. If you are in fertility treatment, discuss any peptide use with your reproductive endocrinologist before your retrieval cycle, because the effect of MOTS-c on oocyte quality is unknown.

Postpartum and lactation: Both peptides should be stopped before attempting conception and not restarted until breastfeeding has completely ended. Transfer into breast milk has not been studied.

Who This Stack May Be Appropriate For, and Who Should Avoid It

Possible candidates (based on proposed mechanisms, not trial evidence)

• Perimenopausal or postmenopausal women with documented insulin resistance or metabolic syndrome who have not responded adequately to lifestyle modification alone.
• Women with PCOS and a metabolic phenotype, under the supervision of a reproductive endocrinologist or obesity medicine specialist.
• Women with BMI >27 and visceral adiposity confirmed by DEXA or waist circumference above 35 inches, for whom FDA-approved GLP-1 medications are not tolerated or contraindicated.

Women who should not use this stack

• Anyone pregnant, trying to conceive, or breastfeeding.
• Women with active or personal history of cancer (GH fragments and IGF-1 pathway involvement require caution; the FDA's guidance on GH and cancer risk applies adjacent to AOD-9604, though the compound does not raise IGF-1).
• Women with type 1 diabetes or brittle type 2 diabetes, given unpredictable effects on glucose from MOTS-c.
• Women with a personal or family history of pituitary tumors.
• Anyone under 18.

Dosing Protocols: What Practitioners Are Using

No regulatory body has established dosing guidelines for either peptide. The following ranges come from practitioner-reported protocols compiled in functional medicine forums and compounding pharmacy consultation notes. They should be read as community practice patterns, not clinical standards.

AOD-9604

Most practitioners prescribe 300 mcg subcutaneously once daily, injected in the morning in a fasted state. Some protocols use 250 to 500 mcg daily. The Phase II trials used oral dosing at 1 mg/kg/day, which does not translate directly to subcutaneous dosing due to bioavailability differences. Cycle length in practitioner protocols is typically 12 to 16 weeks, followed by a 4-week break. There is no published data on whether cycling is necessary or what happens with continuous use beyond 16 weeks.

MOTS-c

Practitioner protocols for MOTS-c range from 5 mg to 10 mg administered subcutaneously or intramuscularly, two to three times per week. Some clinicians start women at 5 mg twice weekly and titrate based on glucose and energy response over 4 weeks. All human dosing is extrapolated from the mouse-to-human conversion in Lee et al. (2015), adjusted by body weight. No pharmacokinetic study has confirmed that this conversion is valid in humans.

Timing Within the Stack

When used together, most practitioners administer AOD-9604 in the morning fasted and MOTS-c on the same morning or on alternate days post-workout. The rationale is to align MOTS-c with periods of high skeletal muscle glucose uptake. This is mechanistically plausible. It has not been tested.

Safety Monitoring: A Practical Protocol for Women

Because neither peptide has established safety data in women, the monitoring approach below is designed to catch the signals most likely to appear based on each peptide's proposed mechanism.

Baseline Labs (Before Starting)

| Lab | Rationale | |---|---| | Fasting glucose and insulin (calculate HOMA-IR) | Baseline insulin sensitivity; MOTS-c may alter this | | HbA1c | Longer-term glycemic snapshot | | IGF-1 | AOD-9604 should not raise this; a rise suggests contamination or a different product | | Fasting lipid panel | Lipolysis changes LDL particle composition | | Comprehensive metabolic panel (LFTs, creatinine) | Liver and kidney health before adding any compound | | TSH and free T4 | Thyroid function; GH-adjacent peptides can affect thyroid axis | | Estradiol, FSH, LH | Establish hormonal context by life stage | | CBC | General safety baseline | | Serum DHEA-S and testosterone (free and total) | Women with PCOS or androgen excess need this anchor | | Pregnancy test | Mandatory before starting |

Monitoring at 6 and 12 Weeks

• Fasting glucose and insulin.
• IGF-1 (to confirm AOD-9604 is not raising it).
• Blood pressure and resting heart rate.
• Symptom diary: injection site reactions, headache, fluid retention, changes in menstrual cycle.

Monitoring at 90 Days and Ongoing

• Full repeat of baseline labs.
• DEXA scan if available to assess body composition changes objectively rather than relying on scale weight.
• The Endocrine Society's clinical practice guideline on growth hormone use recommends IGF-1 monitoring every 3 months for any GH-adjacent intervention, a framework that is reasonable to apply here.

Menstrual Cycle Tracking

Women in their reproductive years should track cycle length, flow, and any new spotting throughout the stack period. Neither peptide has known direct reproductive toxicity, but any intervention that affects insulin sensitivity or GH signaling may secondarily alter LH pulsatility and ovulation. Document any change and report it to your prescriber.

Red Flags That Warrant Stopping Immediately

• IGF-1 rising above the upper limit of the age-adjusted reference range (suggests product contamination with intact GH).
• New or worsening edema.
• Hypoglycemia episodes.
• Injection site nodules that do not resolve within 48 hours.
• Any missed period not explained by another cause.
• Symptoms of intracranial hypertension: persistent headache, visual changes, nausea on waking.

What the Evidence Gap Means for You

Women have been historically under-represented in peptide and GH research. A 2020 analysis in JAMA Internal Medicine found that women represent fewer than 30 percent of participants in metabolic pharmacology trials on average. For AOD-9604 and MOTS-c, the situation is worse. MOTS-c's foundational efficacy study used only male mice. AOD-9604's human trials included women but did not analyze or report their results separately.

This means:

• You cannot assume the fat-loss effect sizes from the Norman et al. Trial apply to you.
• You cannot assume MOTS-c's insulin-sensitizing effect translates from male mice to perimenopausal women.
• You are, in a real sense, participating in an uncontrolled experiment when you use this stack.

That is not a reason to say never use it. It is a reason to monitor carefully, document your results, and choose a prescribing clinician who will engage with your labs rather than simply refill a protocol.

"The honest conversation is that we are using mechanism-based reasoning and clinical pattern recognition, not randomized trial data, when we prescribe this combination for women," says Dr. Maya Okafor, MD, WomanRx medical reviewer and board-certified OB-GYN. "A woman considering this stack deserves to hear that plainly before she agrees."

Regulatory Status and Sourcing Risks

AOD-9604 and MOTS-c are not approved drugs in the United States, Canada, the UK, or the EU. They are sold as research peptides or compounded by compounding pharmacies operating under CLIA-certified laboratory oversight.

The FDA's 2023 guidance on bulk drug substances does not include AOD-9604 or MOTS-c on the approved compounding list, which creates a regulatory gray area for pharmacies that prepare them. Third-party testing data from compounding pharmacies on purity and potency are not uniformly required or published.

If you are sourcing from a compounding pharmacy, ask for the certificate of analysis for every batch. Impurities in injectable peptide preparations carry infection and immune reaction risks that outweigh any theoretical metabolic benefit.